Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes
fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their
levels of fatigue every two weeks while they are participating in this research study. The
questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of
physical measurements for fatigue will be performed before the first dose of sunitinib and
again (4) weeks later to see if there are any changes in physical level of fatigues